NCT01386216View on ClinicalTrials.gov

Safety Study of Bone Marrow Cell Concentrate Prepared Using the Magellan System to Treat Critical Limb Ischemia (CLI)

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

April 30, 2016

Study Completion Date

December 31, 2016

Conditions
Critical Limb Ischemia (CLI)Peripheral Vascular Disease (PVD)
Interventions
DEVICE

Magellan®

Autologous Bone Marrow Cell Concentrate Prepared Using the Magellan System to be injected into the ischemic muscle tissue at 0.5 cc/injection for a total of 12-20 cc.

Trial Locations (1)

43210

The Ohio State University Medical Center, Columbus

Sponsors

Lead Sponsor

Arteriocyte, Inc.
All Listed Sponsors
lead

Arteriocyte, Inc.

INDUSTRY

NCT01386216 - Safety Study of Bone Marrow Cell Concentrate Prepared Using the Magellan System to Treat Critical Limb Ischemia (CLI) | Biotech Hunter | Biotech Hunter